

PHARMACEUTICAL 2023

Carisma Therapeutics Inc. Rank 71 of 446









RealRate





The relative strengths and weaknesses of Carisma Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Carisma Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 68% points. The greatest weakness of Carisma Therapeutics Inc. is the variable Other Assets, reducing the Economic Capital Ratio by 7.5% points.

The company's Economic Capital Ratio, given in the ranking table, is 229%, being 186% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	189,144
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	30,984
Liabilities, Non-Current	0
Other Assets	30
Other Compr. Net Income	-546
Other Expenses	-16,347
Other Liabilities	0
Other Net Income	2,150
Other Revenues	40,000
Property and Equipment	0
Research and Development	38,594
Selling, General and Administrative Expense	39,787

Output Variable	Value in 1000 USD
Assets	189,174
Liabilities	30,984
Expenses	62,034
Revenues	40,000
Stockholders Equity	158,190
Net Income	-19,884
Comprehensive Net Income	-20,157
Economic Capital Ratio	229%

